Needham & Company LLC Reaffirms “Buy” Rating for Shattuck Labs (NASDAQ:STTK)

Needham & Company LLC reaffirmed their buy rating on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued to investors on Friday, Benzinga reports. Needham & Company LLC currently has a $12.00 price target on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $28.00 price target on shares of Shattuck Labs in a report on Thursday.

Shattuck Labs Stock Up 2.9 %

STTK stock opened at $11.09 on Friday. Shattuck Labs has a 52 week low of $1.33 and a 52 week high of $11.62. The stock has a market capitalization of $527.33 million, a PE ratio of -5.75 and a beta of 1.98. The firm has a 50 day moving average of $9.42 and a 200 day moving average of $7.02.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.85%. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Shattuck Labs’s quarterly revenue was up 2200.0% on a year-over-year basis. On average, equities research analysts expect that Shattuck Labs will post -1.85 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Stephen Stout sold 16,004 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the sale, the insider now owns 74,437 shares of the company’s stock, valued at approximately $783,821.61. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Shattuck Labs

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at about $268,000. Reliant Investment Management LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at about $143,000. Franklin Resources Inc. purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at about $11,663,000. Monashee Investment Management LLC purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at about $713,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Shattuck Labs by 79.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after purchasing an additional 5,989 shares during the period. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.